Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98027Q00040

NAICS

541380 - Testing Laboratories and Services

Classification Code

R499

Additional Details
Set Aside

None

Place of Performance

Bethesda, Maryland, UNITED STATES

SourceSAM
The National Institutes of Health (NIH), specifically through its Office of Logistics and Acquisition Operations (OLAO), has issued a presolicitation notice regarding the stability testing of ManNAc drug product produced in Campaigns 5 and 6. This testing is to be conducted under strict regulatory compliance, ensuring the drug’s suitability for upcoming clinical trials managed by the National Human Genome Research Institute (NHGRI). The procurement activity is intended to support the mandatory FDA-required stability testing program for ManNAc, a clinical-grade drug gifted to NHGRI in September 2025. The drug, totaling 48kg in powder-in-sachet form, was manufactured in two distinct campaigns: Campaign 5 (June 2024) and Campaign 6 (September 2024). Since June 2024, Alcami Corporation has been responsible for ongoing stability testing, and NIH intends to continue this arrangement through a non-competitive contract award. The scope of work encompasses comprehensive stability testing services for the ManNAc drug product, adhering to regulatory standards and ensuring data integrity for FDA compliance. The expected deliverables include detailed stability testing reports and documentation that will support NHGRI’s clinical trial activities. The testing must be performed in accordance with all applicable federal regulations and guidelines, maintaining the quality and safety of the drug product throughout its lifecycle. Key requirements for this procurement include: - Proven capability in conducting regulatory-compliant stability testing for clinical-grade pharmaceuticals. - Experience with FDA-mandated testing protocols and documentation. - Ability to provide timely and accurate reporting to support clinical trial readiness. The procurement is classified under NAICS code 541380 (Testing Laboratories and Services), with a size standard of $16.6 million. The place of performance is Bethesda, Maryland, United States. The contract will be awarded under the Federal Acquisition Regulation (FAR) Part 13, utilizing Simplified Acquisition Procedures, and will not exceed the simplified acquisition threshold of $350,000. The statutory authority for this action is FAR Subpart 13.106-1(b)(1), allowing solicitation from a single source and exempting the procurement from full and open competition requirements. The contracting entity is the NIH OLAO, operating under the Department of Health and Human Services. The primary point of contact for this opportunity is Mr. James Law, Contracting Officer, who can be reached at [email protected]. Interested parties are invited to submit capability statements, technical and cost proposals, and relevant business information by November 9, 2026, at 9:00 AM Eastern time, referencing solicitation number 75N98027Q00040. All offerors must be registered in the System for Award Management (SAM). This notice is not a request for competitive proposals; however, responses will be considered to determine whether a competitive procurement is warranted. The government reserves the right to proceed with a non-competitive award based on the responses received. Contractors evaluating this opportunity should note the requirement for regulatory expertise, familiarity with FDA stability testing protocols, and the ability to deliver consistent, high-quality laboratory services. The scope and objectives of the contract will remain constant throughout its lifecycle, focusing on the ongoing stability testing of the ManNAc drug product to support NHGRI’s clinical research initiatives.